Phase 1Recruiting
A Study in Healthy Men to Test Whether Carbamazepine Influences the Amount of Verducatib in the Blood
An Open-label, Fixed-sequence, Two-period Phase I Trial to Evaluate the Effect of Multiple Oral Doses of Carbamazepine, a Strong CYP3A4 Inducer, on the Pharmacokinetics of Verducatib at Steady State in Healthy Male Trial Participants
- Sponsor
- Boehringer Ingelheim (Industry)
- Enrollment
- 20 planned
- Conditions
- Healthy
- Interventions
- Verducatib; Carbamazepine
- Ages
- adults
- Registry
- NCT07781631
Full record on ClinicalTrials.gov
From the registry
The main objective of this trial is to investigate the effect of carbamazepine, a strong CYP3A4 inducer on the pharmacokinetics of verducatib at steady state.
Primary outcomes
- Area under the concentration-time curve of the analyte in plasma at steady state over a uniform dosing interval τ (AUCτ,ss)
- Maximum measured concentration of the analyte in plasma at steady state over a uniform dosing interval τ (Cmax,ss)
History
Study completion expected
Primary completion expected
Last registry update
Started
Registered